MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) EVP Thomas M. Ross sold 15,476 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $4.54, for a total value of $70,261.04. Following the completion of the sale, the executive vice president now owns 25,000 shares of the company’s stock, valued at approximately $113,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
MaxCyte Stock Down 8.3 %
Shares of MaxCyte stock opened at $4.08 on Thursday. The company has a market cap of $427.68 million, a PE ratio of -11.66 and a beta of 1.42. The business has a 50 day moving average of $4.43 and a 200 day moving average of $4.42. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55.
MaxCyte (NASDAQ:MXCT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.05. The business had revenue of $10.43 million during the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. During the same quarter in the prior year, the company earned ($0.10) earnings per share. On average, research analysts anticipate that MaxCyte, Inc. will post -0.5 earnings per share for the current year.
Hedge Funds Weigh In On MaxCyte
Analyst Ratings Changes
Separately, Stephens reiterated an “overweight” rating and issued a $11.00 price objective on shares of MaxCyte in a research report on Tuesday, April 23rd.
Check Out Our Latest Research Report on MXCT
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Read More
- Five stocks we like better than MaxCyte
- How to Start Investing in Real Estate
- What Are Bonds? A High-Level Overview
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- What to Know About Investing in Penny Stocks
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.